{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:54:53Z","timestamp":1785894893456,"version":"3.56.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260163"],"award-info":[{"award-number":["82260163"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370895"],"award-info":[{"award-number":["82370895"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.mce.2026.112845","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:06:45Z","timestamp":1781050005000},"page":"112845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The mineralocorticoid receptor and its antagonist finerenone regulate hepatic lipid accumulation via the AMPK\/SREBP1\/FASN signaling"],"prefix":"10.1016","volume":"620","author":[{"given":"Shanpan","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuemei","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanling","family":"Que","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueling","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengni","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liushuang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiying","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7930-2228","authenticated-orcid":false,"given":"Hidenori","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5909-5759","authenticated-orcid":false,"given":"Jidong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.mce.2026.112845_bib1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3390\/ijms21020552","article-title":"Beneficial effects of SREBP decoy oligodeoxynucleotide in an animal model of hyperlipidemia","volume":"21","author":"An","year":"2020","journal-title":"IJMS"},{"issue":"8","key":"10.1016\/j.mce.2026.112845_bib2","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3390\/biomedicines13081792","article-title":"The role of aldosterone and the mineralocorticoid receptor in metabolic dysfunction-associated steatotic liver disease","volume":"13","author":"Barigou","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.mce.2026.112845_bib3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/ijerph20010012","article-title":"Impact of mineralocorticoid receptor gene NR3C2 on the prediction of functional classification of left ventricular remodeling and arrhythmia after acute myocardial infarction","volume":"20","author":"Braukyliene","year":"2022","journal-title":"IJERPH"},{"issue":"3","key":"10.1016\/j.mce.2026.112845_bib4","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1152\/physrev.00020.2012","article-title":"11\u03b2-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action","volume":"93","author":"Chapman","year":"2013","journal-title":"Physiol. Rev."},{"issue":"5","key":"10.1016\/j.mce.2026.112845_bib5","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr. Pract."},{"issue":"7","key":"10.1016\/j.mce.2026.112845_bib6","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"15","key":"10.1016\/j.mce.2026.112845_bib7","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.7150\/ijbs.65044","article-title":"Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies","volume":"18","author":"Fang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.mce.2026.112845_bib8","article-title":"Research progress on AMPK in the pathogenesis and treatment of MASLD","volume":"16","author":"Feng","year":"2025","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.mce.2026.112845_bib9","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.mce.2026.112845_bib10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.med.48.1.231","article-title":"Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance","volume":"48","author":"Funder","year":"1997","journal-title":"Annu. Rev. Med."},{"issue":"10397","key":"10.1016\/j.mce.2026.112845_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"National burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021","volume":"402","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.mce.2026.112845_bib12","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.mce.2026.112845_bib13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11906-012-0297-0","article-title":"The ubiquitous mineralocorticoid receptor: clinical implications","volume":"14","author":"Hawkins","year":"2012","journal-title":"Curr. Hypertens. Rep."},{"issue":"1","key":"10.1016\/j.mce.2026.112845_bib14","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cvr\/cvp191","article-title":"Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice","volume":"84","author":"Hirata","year":"2009","journal-title":"Cardiovasc. Res."},{"issue":"9","key":"10.1016\/j.mce.2026.112845_bib15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","article-title":"Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis","volume":"8","author":"Huang","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.mce.2026.112845_bib16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","article-title":"Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study","volume":"165","author":"Huang","year":"2023","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.mce.2026.112845_bib17","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance","volume":"79","author":"Hutchison","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.mce.2026.112845_bib18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/bs.vh.2018.10.005","article-title":"Adipocyte mineralocorticoid receptor","volume":"109","author":"Infante","year":"2019","journal-title":"Vitam. Horm."},{"issue":"18","key":"10.1016\/j.mce.2026.112845_bib19","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"issue":"5","key":"10.1016\/j.mce.2026.112845_bib20","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"16","key":"10.1016\/j.mce.2026.112845_bib21","doi-asserted-by":"crossref","first-page":"9243","DOI":"10.3390\/ijms23169243","article-title":"Nonsteroidal mineralocorticoid receptor antagonism by Finerenone\u2014translational aspects and clinical perspectives across multiple organ systems","volume":"23","author":"Kolkhof","year":"2022","journal-title":"IJMS"},{"issue":"4","key":"10.1016\/j.mce.2026.112845_bib22","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach","volume":"28","author":"Le","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"issue":"6","key":"10.1016\/j.mce.2026.112845_bib23","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s12072-020-10096-0","article-title":"Exosomal miR-199a-5p promotes hepatic lipid accumulation by modulating MST1 expression and fatty acid metabolism","volume":"14","author":"Li","year":"2020","journal-title":"Hepatol. Int."},{"issue":"12","key":"10.1016\/j.mce.2026.112845_bib24","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","article-title":"Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Loomba","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.mce.2026.112845_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1125693","article-title":"Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus","volume":"14","author":"Lv","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"2","key":"10.1016\/j.mce.2026.112845_bib26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.mce.2026.112845_bib27","doi-asserted-by":"crossref","first-page":"12450","DOI":"10.1096\/fj.202000164R","article-title":"The novel non\u2010steroidal MR antagonist finerenone improves metabolic parameters in high\u2010fat diet\u2010fed mice and activates brown adipose tissue via AMPK\u2010ATGL pathway","volume":"34","author":"Marzolla","year":"2020","journal-title":"FASEB J."},{"issue":"12","key":"10.1016\/j.mce.2026.112845_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100676","article-title":"Targeting acetyl-CoA carboxylases for the treatment of MASLD","volume":"65","author":"Mateo-Mar\u00edn","year":"2024","journal-title":"J. Lipid Res."},{"issue":"23","key":"10.1016\/j.mce.2026.112845_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316654","article-title":"Transcriptomics of MASLD pathobiology in African American patients in the Washington DC area","volume":"24","author":"Mondal","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mce.2026.112845_bib30","article-title":"A mineralocorticoid receptor deficiency in myeloid cells reduces liver steatosis by impairing activation of CD8+ T cells in a nonalcoholic steatohepatitis mouse model","volume":"16","author":"Mu\u00f1oz-Durango","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.mce.2026.112845_bib31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.kisu.2021.11.004","article-title":"Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease","volume":"12","author":"Nakamura","year":"2022","journal-title":"Kidney Int. Suppl."},{"issue":"1","key":"10.1016\/j.mce.2026.112845_bib32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/dom.15305","article-title":"Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: a FIDELITY subgroup analysis","volume":"26","author":"Perakakis","year":"2024","journal-title":"Diabetes Obes. Metabol."},{"issue":"9","key":"10.1016\/j.mce.2026.112845_bib33","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1111\/liv.12794","article-title":"Beneficial effects of mineralocorticoid receptor blockade in experimental non\u2010alcoholic steatohepatitis","volume":"35","author":"Pizarro","year":"2015","journal-title":"Liver Int."},{"issue":"12","key":"10.1016\/j.mce.2026.112845_bib34","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/dom.12989","article-title":"Effects of combined low\u2010dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non\u2010invasive indices of steatosis and fibrosis, and adipokine levels in non\u2010alcoholic fatty liver disease: a randomized controlled trial","volume":"19","author":"Polyzos","year":"2017","journal-title":"Diabetes Obes. Metabol."},{"issue":"1","key":"10.1016\/j.mce.2026.112845_bib35","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and Obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.mce.2026.112845_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13666","article-title":"Rapamycin\/metformin co\u2010treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice","volume":"21","author":"Reifsnyder","year":"2022","journal-title":"Aging Cell"},{"issue":"9","key":"10.1016\/j.mce.2026.112845_bib37","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.mce.2026.112845_bib38","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00125-023-06031-1","article-title":"Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists","volume":"67","author":"Savarese","year":"2024","journal-title":"Diabetologia"},{"issue":"13","key":"10.1016\/j.mce.2026.112845_bib39","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1111\/bph.15784","article-title":"Mineralocorticoid receptors in non-alcoholic fatty liver disease","volume":"179","author":"Schreier","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.mce.2026.112845_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154561","article-title":"Pterostilbene alleviated NAFLD via AMPK\/mTOR signaling pathways and autophagy by promoting Nrf2","volume":"109","author":"Shen","year":"2023","journal-title":"Phytomedicine"},{"issue":"4","key":"10.1016\/j.mce.2026.112845_bib41","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"10.1016\/j.mce.2026.112845_bib42","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41580-022-00547-x","article-title":"New insights into activation and function of the AMPK","volume":"24","author":"Steinberg","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"2","key":"10.1016\/j.mce.2026.112845_bib43","article-title":"Cordycepin ameliorates nonalcoholic steatohepatitis by activation of the AMP-activated protein kinase signaling pathway","volume":"74","author":"T","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.mce.2026.112845_bib44","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.mce.2026.112845_bib45","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s42255-024-01043-6","article-title":"An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"6","author":"Vacca","year":"2024","journal-title":"Nat. Metab."},{"issue":"11","key":"10.1016\/j.mce.2026.112845_bib46","doi-asserted-by":"crossref","first-page":"E1415","DOI":"10.1152\/ajpendo.00419.2013","article-title":"Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet","volume":"305","author":"Wada","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metabol."},{"issue":"12","key":"10.1016\/j.mce.2026.112845_bib47","first-page":"4677","article-title":"Effect of aldosterone and its antagonist on the expression of PAI-1 and TGF-\u03b21 in rat hepatic stellate cells","volume":"7","author":"Wang","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"6","key":"10.1016\/j.mce.2026.112845_bib48","first-page":"536","article-title":"Evolution of mineralocorticoid receptor antagonists in the treatment of chronic kidney disease associated with type 2 diabetes mellitus","volume":"6","author":"Wish","year":"2022","journal-title":"Mayo Clin. Proc.: Innovat. Qual. Outcomes"},{"key":"10.1016\/j.mce.2026.112845_bib49","series-title":"World Health Organization Diabetes [WHO web site] [Internet]","article-title":"World health organization diabetes","year":"2025"},{"issue":"4","key":"10.1016\/j.mce.2026.112845_bib51","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.mce.2026.112845_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1476029","article-title":"A comprehensive review of finerenone\u2014a third-generation non-steroidal mineralocorticoid receptor antagonist","volume":"11","author":"Zhai","year":"2024","journal-title":"Front. Cardiovasc. Med."}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030372072600122X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030372072600122X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:42:50Z","timestamp":1785894170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030372072600122X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":51,"alternative-id":["S030372072600122X"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2026.112845","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The mineralocorticoid receptor and its antagonist finerenone regulate hepatic lipid accumulation via the AMPK\/SREBP1\/FASN signaling","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mce.2026.112845","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112845"}}